高危N2至N3期鼻咽癌诱导化疗对比辅助化疗的3期随机临床试验
两组3年无进展生存率分别为73.5%与70.4%,差异无统计学意义(分层HR 0.86,95%CI 0.58-1.27,P=0.45)。两种策略均有效,临床医生应与患者讨论诱导或辅助化疗的潜在风险与获益。
要点
- 诱导-同期组3年无进展生存率73.5%,同期-辅助组70.4%,差异无统计学意义(P=0.45)。
- 两组最常见的3级及以上短期不良事件为白细胞减少、中性粒细胞减少和黏膜炎,发生率相近。
- 诱导-同期组有2例治疗相关死亡,同期-辅助组无治疗相关死亡。
核心结论
- 在高危N2至N3期鼻咽癌中,诱导-同期化疗相比同期-辅助化疗未显著改善无进展生存期。
- 两种治疗策略均有效,临床医生应与患者讨论诱导化疗或辅助化疗的潜在风险与获益,以提供最合适的治疗。
研究设计与样本
- 开放标签、随机、3期临床试验,在中国中山大学肿瘤防治中心开展,时间为2017年11月20日至2021年3月19日。
- 纳入年龄18至65岁、T1-4N2-3M0期且治疗前EB病毒DNA水平≥1500拷贝/mL的患者。
- 患者随机接受3周期紫杉醇-顺铂-氟尿嘧啶诱导化疗后同期放化疗,或同期放化疗后3周期顺铂-氟尿嘧啶辅助化疗。
- 主要终点为研究者局部评估的3年无进展生存率,定义为从随机分组至记录到局部或区域复发、远处转移或任何原因死亡的时间。
主要发现
- 中位随访60.4个月(IQR 58.2-62.6),3年无进展生存率诱导-同期组为73.5%(95%CI 65.9%-79.6%),同期-辅助组为70.4%(95%CI 62.7%-76.8%),分层风险比0.86(95%CI 0.58-1.27;P=0.45)。
- 最常见的3级及以上短期不良事件:白细胞减少诱导-同期组53/160例(33.1%) vs 同期-辅助组47/142例(33.1%);中性粒细胞减少52例(32.5%) vs 32例(22.5%);黏膜炎47例(29.4%) vs 42例(29.6%)。
- 最常见的3级及以上晚期不良事件为听觉或听力丧失:诱导-同期组10例(6.3%) vs 同期-辅助组12例(8.5%)。
- 诱导-同期组有2例患者死于治疗相关毒性反应;同期-辅助组无治疗相关死亡。
临床怎么用
- 作者认为,两种治疗策略均有效,临床医生应与患者讨论诱导化疗或辅助化疗的潜在风险与获益,以提供最合适的治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It remains uncertain which chemotherapy sequence is more effective for locoregionally advanced nasopharyngeal carcinoma. OBJECTIVE: To compare the efficacy and safety of induction-concurrent with concurrent-adjuvant chemotherapy in high-risk N2 to N3 nasopharyngeal carcinoma. DESIGN, SETTING, AND PARTICIPANTS: In this open-label, randomized, phase 3 clinical trial conducted at Sun Yat-sen University Cancer Center (China) from November 20, 2017, to March 19, 2021, patients aged 18 to 65 years with stage T1-4N2-3M0 and a pretreatment Epstein-Barr virus DNA level of 1500 or more copies/mL were enrolled. The data were analyzed from December 2024 to March 2025. INTERVENTION: The patients were randomly assigned to receive 3 cycles of paclitaxel-cisplatin-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy followed by 3 cycles of cisplatin-fluorouracil adjuvant chemotherapy. MAIN OUTCOME AND MEASURE: The primary end point was 3-year progression-free survival, assessed locally by the investigator and defined as the time from random assignment to documented local or regional relapse, distant metastasis, or death of any cause, whichever occurred first. RESULTS: A total of 162 patients (median [IQR] age, 44 [34-53] years; 40 female individuals [24.7%]) were assigned to the induction-concurrent group and 162 (median [IQR] age, 45 [37-52] years; 36 female individuals [22.2%]) to the concurrent-adjuvant group. Regarding the data cutoff (October 8, 2024), the median (IQR) follow-up period was 60.4 (58.2-62.6) months. The 3-year progression-free survival rates were 73.5% (95% CI, 65.9%-79.6%) in the induction-concurrent group and 70.4% (95% CI, 62.7%-76.8%) in the concurrent-adjuvant group (stratified hazard ratio, 0.86; 95% CI, 0.58-1.27; P = .45). The most common short-term grade 3 or worse adverse events were leukopenia (53 of 160 [33.1%] in the induction-concurrent group vs 47 of 142 [33.1%] in the concurrent-adjuvant group), neutropenia (52 [32.5%] vs 32 [22.5%], respectively), and mucositis (47 [29.4%] vs 42 [29.6%], respectively). The most common grade 3 or worse late adverse event was auditory or hearing loss (10 [6.3%] vs 12 [8.5%], respectively). Two patients in the induction-concurrent group died of treatment-related toxic effects. No treatment-related death occurred in the concurrent-adjuvant group. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that induction-concurrent chemotherapy did not significantly improve progression-free survival compared with concurrent-adjuvant chemotherapy in high-risk N2 to N3 nasopharyngeal carcinoma. Both treatment strategies were effective, and clinicians should discuss with the patients about the potential risks and benefits of the induction chemotherapy or adjuvant chemotherapy to provide the most appropriate treatment for patients with high-risk features. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03306121.
引用
- Guo SS, Li XY, Liu LT, et al. Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 40531520. doi:10.1001/jamaoncol.2025.1597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。